Despite these clinical milestones and ongoing innovation, including first-in-human studies of new oncology drugs, Pfizer Inc.

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

Payal Sahni Becher is currently the Chief People Experience Officer & Executive VP at Pfizer Inc. She started this position in 2022. Prior to her current role, she obtained a graduate degree from ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Gujarat Gas Limited, Quess Corp, Power Finance Corporation, and Eris Lifesciences Limited will also report their quarterly ...

Stock Market Today: The Indian stock market opened on a cautious note on Monday, May 19, as they defied the global stock ...